Lozano, Rebeca
Castro, Elena
Aragón, Isabel M.
Cendón, Ylenia
Cattrini, Carlo
López-Casas, Pedro P.
Olmos, David http://orcid.org/0000-0002-7003-4826
Funding for this research was provided by:
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (CM17/00221, JR18/00011, PI19/01475, PI16/01565, PI19/01380)
U.S. Department of Defense (W81XWH-18-1-0193, W81XWH-18-1-0193)
Prostate Cancer Foundation (PCF-YIA2017, PCF-YIA2014)
Sociedad Española de Oncología Médica Fundación CRIS Contra el Cáncer
Ministerio de Educación, Cultura y Deporte (FPU15/05126)
European Society for Medical Oncology (ESMO fellowship 2019)
Ministerio de Economía y Competitividad (RYC-2015-18625)
Fundación CRIS Contra el Cáncer Fundación Científica de la Asociación Española Contra el Cáncer
Article History
Received: 29 March 2020
Revised: 3 August 2020
Accepted: 14 September 2020
First Online: 27 October 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: Not applicable.
: R.L. declares speaker fees from Roche, Janssen and Sanofi, and travel support from Roche and Janssen. E.C. declares honoraria from Astellas Pharma, AstraZeneca, Bayer, Clovis, Janssen-Cilag, Pfizer and Roche, consulting or Advisory Roles for AstraZeneca, Bayer, Janssen and MSD, research funding from AstraZeneca (Inst), Bayer (Inst) and Janssen (Inst) and travel support from Bayer, Janssen, Roche and Astellas Pharma. C.C. declares travel support from Ipsen and Novartis. D.O. declares honoraria from Bayer, Janssen and Sanofi, consulting or advisory role from AstraZeneca, Bayer, Clovis Oncology, Daiichi-Sankyo Janssen, MSD and Roche, research funding from Astellas (Inst), AstraZeneca (Inst), Bayer (Inst), Genentech (Inst), Janssen (Inst), Medivation (Inst), MSD (Inst), Pfizer (Inst), F. Hoffman-Roche (Inst) and Tokai Pharmaceuticals (Inst) and travel support from Bayer, Ipsen, Janssen and F. Hoffman-Roche. I.M.A., Y.C. and P.P.L.-C. do not have any relationships to disclose.
: The authors at the Prostate Cancer Clinical Research Unit (CNIO) and the Genitourinary Cancer Translational Research Group (IBIMA) are supported by: grants from “Instituto de Salud Carlos III” (PI16/01565 and PI19/01380 to D.O., JR18/00011 and PI19/01475 to E.C., CM17-00221 to R.L.), a Department of Defense US IMPACT award (W81XWH-18-1-0193), a CRIS Excellence in research award (E19-26 to D.O.), a “Fundación Científica de la AECC” research grant (PROYE19054OLMO to D.O.), a 2017 Prostate Cancer Foundation Young investigator Award to E.C., grants from “Ministerio de Economía, Industria y Competitividad” (RYC-2015-18625 to D.O. and FJCI-2016-28121 to I.M.A), a grant from “Ministerio de Educación, Cultura y Deportes (FPU15/05126 to Y.C.), a 2019 ESMO clinical research fellowship to C.C. and unrestricted grants from “Fundación CRIS contra el Cáncer”.